Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Thomas, McNerney raises first fund

Thomas, McNerney & Partners raised $216 million for its first fund,

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE